Patterns of Spontaneous Adverse Events Reporting on Human Papillomavirus Vaccines according to the Applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017 |
Kim, Myo-Song
(College of Pharmacy, Chung-Ang University)
You, Seung-Hun (College of Pharmacy, Chung-Ang University) Park, Hye Min (College of Pharmacy, Chung-Ang University) Lee, Min-Taek (College of Pharmacy, Chung-Ang University) Kang, Ye-Jin (College of Pharmacy, Chung-Ang University) Koo, Hyunji (College of Pharmacy, Chung-Ang University) Jung, Sun-Young (College of Pharmacy, Chung-Ang University) |
1 | Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4(1):46-55. DOI |
2 | Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine 2017;35(43):5753-5. DOI |
3 | Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009;15(1):116-9. DOI |
4 | Yonee C, Toyoshima M, Maegaki Y, et al. Association of Acute Cerebellar Ataxia and Human Papilloma Virus Vaccination: A Case Report. Neuropediatrics 2013;44(05):265-7. DOI |
5 | Tomljenovic L, Shaw C. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental. Pharmaceut Reg Affairs S 2012;12:2. |
6 | World Health Organization. Vaccine safety basics e-learning course. Available from https://vaccine-safety-training.org/. Accessed January 21, 2020. |
7 | Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance; Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Available from https://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf. Accessed March 24, 2020. |
8 | European Medicines Agency. Guideline on good pharmacovigilance practices (GVP); Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinegood-pharmacovigilance-practices-gvp-product-populationspecific-considerations-i-vaccines_en.pdf. Accessed March 24, 2020. |
9 | Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012;30(11):2020-3. DOI |
10 | Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7):750-7. DOI |
11 | Choe YJ, Cho H, Bae G-R, Lee J-K. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine 2011;29(11):2066-70. DOI |
12 | Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 22.1. Available from https://www.meddra.org/sites/default/files/guidance/file/000356_smq_intguide_22_1.pdf. Accessed March 24, 2020. |
13 | van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11(1):3-10. DOI |
14 | Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie 2019;74(2):225-32. DOI |
15 | Scotti L, Romio S, Ghirardi A, et al. Should methods of correction for multiple comparisons be applied in pharmacovigilance? Epidemiol Biostat Public Health 2015;12(4):e11654. |
16 | Ministry of Food and Drug Safety. Available from https://nedrug.mfds.go.kr/. Accessed January 20, 2020 |
17 | Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 2018;132(1): 35-44. DOI |
18 | Gidudu J, Kohl KS, Halperin S, et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008;26(52):6800-13. DOI |
19 | Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003;52(1):1-24. |
20 |
Enforcement Regulations of the Infectious Disease Control and Prevention Act [Annexed Form No. 2] |
21 | Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol 2015;34(7):1225-31. DOI |
22 | Melo Gomes S, Glover M, Malone M, Brogan P. Vasculitis following HPV immunization. Rheumatology 2012;52(3):581-2. DOI |
23 | Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Noren GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in . Drug Saf 2017;40(1):81-90. DOI |
24 | Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 2015;33(22):2602-5. DOI |
25 | Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013. Vaccine 2015;33(28):3171-8. DOI |
26 | Kinoshita T, Abe R, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014;53(19):2185-200. DOI |
27 | World Health Organization. Safety update of HPV vaccines. Available from https://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/. Accessed January 20, 2020. |
28 | Korea Centers for Disease Control and Prevention. Available from https://nip.cdc.go.kr/irgd/introduce.do?MnLv1=3&MnLv2=6&MnLv3=3. Accessed January 20, 2020. |
29 | Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015;33(29):3422-8. DOI |
30 | Top KA, Constantinescu CM, Lafleche J, et al. Applicability of the Brighton Collaboration case definition for seizure after immunization in active and passive surveillance in Canada. Vaccine 2013;31(48):5700-5. DOI |
31 | Public Health Agency of Canada. Reporting Adverse Events Following Immunization (AEFI) in Canada: User Guide to completion and submission of the AEFI reports 2019. Available from https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/reporting-adverse-events-followingimmunization/user-guide-completion-submission-aefi-reports/aefiuser-guide-jan-22-2020-eng.pdf. Accessed March 2, 2020. |
32 | Law BJ, Lafleche J, Ahmadipour N, Anyoti H. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012. Can Commun Dis Rep 2014;40(Suppl 3):7-23. |
33 | Chung SY, Jung SY, Shin JY, Park BJ. The role of the KIDS for enhancing drug safety and risk management in Korea. J Korean Med Assoc 2012;55(9):861-8. DOI |
34 | Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18(6):427-36. DOI |